STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDlearn · Body

Menopause and the years around it

Also known as

perimenopause · hot flashes · night sweats · HRT · hormone therapy · menopause transition · vasomotor · midlife bone · menopause sleep · the change

Named sources. May be wrong or incomplete. Not medical, legal, financial, or other professional advice.

Open in the directory ↗

Name peri versus menopause, heat, sleep, bone, and hormones.

An adult sitting by a window with a mug, looking outward in ordinary daylight

What would help today?

Tell peri from menopause by the last period
Perimenopause
The transition years when cycles change before the final period.
Menopause
Twelve months without a period is the usual clinical definition when hormonal contraception is not masking cycles.

The years around the last period are easy to mix up because people use menopause as a catch-all word. The National Institute on Aging treats menopause as a normal aging stage: periods have stopped for a full year, and the years of changing cycles before that are the menopausal transition, often called perimenopause. Sioban Harlow and the STRAW+10 workshop staged those years around the final menstrual period, using bleeding pattern as the main marker rather than one blood test. NICE guidance for people 45 and over with typical symptoms likewise uses the story of cycles and heat, not routine follicle-stimulating hormone tests. If cycles have become irregular, you may be in the transition; if twelve months have passed without a period and you are not using hormonal contraception, menopause is the usual clinical name. That naming helps a visit. It is not a home diagnosis or a fertility promise.

Sources 5
Make sense of heat that lasts years, not weeks
Frequent hot flashes and night sweats
Median total duration in SWAN: 7.4 years.
After the final period
Median 4.5 years among participants whose final period was observed; individual courses differ.
If they disrupt work or sleep
Bring the symptoms to a clinician instead of waiting for a fixed two-year stop date.

A hot flash is a sudden wave of heat, often in the face, neck, and chest, sometimes with flushing and sweat; a night sweat is the same event during sleep. Researchers call these vasomotor symptoms. Nancy Avis and colleagues in the Study of Women's Health Across the Nation followed midlife women with frequent symptoms and found a median total duration of 7.4 years, with 4.5 years after the final period among those with an observed last period. People who first had frequent heat while still cycling tended to have the longest course. Rebecca Thurston studies how these events sit in daily life and later health research; the duration finding is from SWAN, not a promise about one person. If heat is still interrupting work or sleep after the two-year folklore window, that pattern matches the cohort more than it contradicts it. Bring bothersome heat to a clinician rather than waiting for an automatic stop date.

Sources 3
Get help when nights stay broken around the transition
A useful care option
Ask about CBT-I—structured cognitive behavioral therapy for insomnia—and evaluation of other causes of broken sleep.
What the trial found
Sleep improved through 24 weeks; daily hot-flash counts did not differ, although heat interfered less.

Night sweats can wake a person, and some midlife insomnia continues even when heat is not the whole story. Hadine Joffe's research program treats sleep, mood, and thermoregulatory symptoms as related midlife problems rather than one slogan. In the MsFLASH trial, Susan McCurry and colleagues randomized 106 perimenopausal or postmenopausal women with insomnia and daily hot flashes to telephone cognitive behavioral therapy for insomnia or menopause education. Insomnia scores fell more with CBT-I, and the sleep gain lasted to 24 weeks; daily hot-flash counts did not differ, though interference from heat improved. CBT-I means a structured program of sleep timing, bed use, and thought-and-behavior work, not a pep talk. If a full-looking night still leaves you unrefreshed, or you cannot stay asleep, ask a clinician about insomnia care and about causes that need their own evaluation. This page is not a sleep clinic.

Sources 2
Keep muscle and bone in the midlife week
Muscle and bone
Keep strength work in the week; supervised training has evidence for bone density and function in screened participants.
Bone-density screening
Recommended for women 65 and older and younger postmenopausal women at increased fracture risk.
Hormone therapy
Can prevent bone loss and fracture in appropriate users; it is one option to discuss, not a requirement.

After the last period, average bone mineral density falls faster for a stretch of years, and unused muscle is easier to lose. The Menopause Society 2022 hormone-therapy statement records that hormone therapy can prevent bone loss and fracture in appropriate users; that is a documented effect, not a requirement to take hormones. The U.S. Preventive Services Task Force recommends bone-density screening for women 65 and older and for younger postmenopausal women at increased fracture risk. Belinda Beck's LIFTMOR trial found that eight months of twice-weekly supervised high-intensity resistance and impact training improved lumbar-spine density and function versus a low-intensity home program in screened postmenopausal women with low bone mass. Wendy Kohrt studies how estrogen and exercise jointly affect midlife body composition. Strength work is a health practice with its own evidence. It is not a hot-flash cure and not a substitute for a fracture-risk conversation.

Sources 5

Name peri versus menopause, see what the field found about heat, sleep, bone, and hormones, then take one next step.

Good to know. This is a reading companion, not a diagnosis, hormone prescription, or clinic visit. Persistent or bothersome heat, night sweats, broken sleep, early period stop, or worry about bone belong with a qualified clinician who can take a history and tailor care. After more than a year without a period, new bleeding or spotting needs prompt medical review. Periods that stop before 45, very heavy or closely stacked bleeding, and sudden severe symptoms also need a person, not a page. Do not start, stop, or change hormone therapy, other medicines, or a training plan from this text. Chest pain, fainting, one-sided weakness, or sudden breathlessness need emergency care. This page does not treat one body or promise an outcome.

What the research found

  • Name menopause after twelve quiet months. The National Institute on Aging says you know menopause has occurred when there has been no period or spotting for a full year; the U.S. average age is about 52, with a wide range. STRAW+10 places the final menstrual period at the center of staging and treats the twelve months after that last bleed as the close of perimenopause in ordinary speech. NICE tells clinicians not to rely on routine FSH tests to name the stage in otherwise healthy people 45 and over with typical symptoms, because hormone levels swing during the transition. Nanette Santoro has spent decades explaining that swing in SWAN and in clinic teaching. Use the calendar and the symptom story first. A single blood draw is not a verdict, and a page cannot date your last period for you.
    Sources 4
  • Expect frequent heat to last years for many people. Vasomotor symptoms are the field name for hot flashes and night sweats. Avis reported a median 7.4 years of frequent symptoms in SWAN, not a two-year cap. African American women in that analysis had a longer median duration than other groups studied, which is a reminder that averages hide real differences. Thurston and Janet Carpenter have helped the field treat bother and interference as outcomes, not only a daily tally. Crandall, Mehta, and Manson estimated that about half to three-quarters of women have vasomotor symptoms during the transition. If heat is still present years after the last period, that can still be the transition rather than a personal failure. Duration is descriptive. It does not by itself decide treatment.
    Sources 4
  • Treat hormone therapy as the strongest option for bothersome heat, not a requirement. The 2022 hormone-therapy position statement of The North American Menopause Society, now The Menopause Society, says hormone therapy remains the most effective treatment for vasomotor symptoms and has been shown to prevent bone loss and fracture. Stephanie Faubion chaired that advisory panel. Crandall's 2023 JAMA review estimated about a 75 percent reduction in vasomotor frequency with systemic estrogen, with or without a progestogen. JoAnn Manson's 2024 WHI review says hormone therapy is appropriate for bothersome vasomotor symptoms in early menopause for women without contraindications who want it, and is not supported as a way to prevent heart disease or other chronic disease. That is a bothersome-symptom option with named limits. It is not a rule that every midlife adult must take hormones.
    Sources 5
  • Use recommended nonhormone options when hormones are not the path. Chrisandra Shufelt led The Menopause Society's 2023 nonhormone position statement. Recommended options with the strongest evidence ratings included cognitive-behavioral therapy, clinical hypnosis, selected SSRI and SNRI medicines, gabapentin, and fezolinetant, with oxybutynin, weight loss, and stellate ganglion block in lower-rated rows. Myra Hunter's menopause-specific CBT work is one reason CBT sits in that recommended list: it often reduces how much heat interferes with life. The same statement does not recommend herbal supplements, soy as treatment, acupuncture, or exercise as vasomotor therapy. A nonhormone path is a real field option for people who cannot take estrogen, prefer not to, or want something in addition. Medicine choice, dose, and contraindications belong with a prescriber.
    Sources 3
  • Use structured insomnia care when sleep stays hard. Cognitive behavioral therapy for insomnia is a time-limited program that changes sleep schedule, time in bed, and the habits and thoughts that keep a person struggling for sleep. McCurry's MsFLASH trial showed larger insomnia-score drops with telephone CBT-I than with menopause education in women who also had hot flashes, with benefits still visible at six months. Joffe notes that vasomotor events contribute to awakenings and that the hormone environment may also relate to sleep disturbance after those events are accounted for. Treating only the flash does not automatically repair an insomnia pattern, and treating only sleep does not erase heat. If snoring with gasping, repeated unintended sleep, or a sudden change in function is present, that is a different evaluation. Ask for the matching kind of help.
    Sources 2
  • Keep strength work and bone screening in view. World Health Organization adult guidance includes muscle-strengthening activity for major muscle groups on two or more days each week. That population target is not a personal program. USPSTF 2025 guidance recommends DXA screening for women 65 and older and for younger postmenopausal women at increased osteoporotic-fracture risk. LIFTMOR tested a short, supervised, heavy lifting and impact session twice a week in screened women with low bone mass and found better spine density and function than a low-intensity control. Kohrt’s work keeps estrogen, exercise, and body composition in the same midlife picture without turning one gym session into a hormone. Strength training supports muscle and can support bone when the loading and supervision fit the person. It does not replace fracture-risk care or guarantee a density number.
    Sources 4

Where experts still disagree

  • Weigh hormone therapy by age, timing, and the reason for use. The 2002 WHI estrogen-plus-progestin trial, led for publication by Jacques Rossouw, enrolled postmenopausal women with a mean age in the early sixties and asked whether combined oral hormones prevented chronic disease. Overall risks exceeded benefits for that prevention question. Later age-stratified WHI analyses, synthesized by Manson in 2013 and again in 2024, found lower absolute adverse-event rates in women aged 50 to 59 or within about ten years of menopause than in older initiators, while still not supporting hormones as heart-disease prevention. The Menopause Society 2022 statement describes a more favorable benefit-risk balance for most healthy symptomatic women younger than 60 and within ten years of onset, and a less favorable balance after that window because of higher absolute risks of coronary disease, stroke, clots, and dementia. Age bands are group findings. They do not replace an individual history.
    Sources 5
  • Review how long to continue with a clinician over time. Some clinicians stop systemic hormones at five years; some continue while bothersome symptoms persist. The 2022 Menopause Society statement says longer duration should be for documented indications such as persistent vasomotor symptoms, with shared decision-making and periodic reevaluation. It does not set one mandatory stop date for every user. Manson’s WHI practice review still rejects using the same medicines as lifelong chronic-disease prevention. Monica Christmas, in public Menopause Society education, emphasizes matching the regimen to the person in front of you rather than to a slogan. The live disagreement is duration and purpose, not whether symptoms can be treated. Revisit the reason you started, current symptoms, and current risks instead of treating a round anniversary as a medical law.
    Sources 3
  • Prefer regulated hormone products over custom compounded mixes. Compounded bioidentical hormone therapy is a pharmacist-mixed recipe promoted as more natural or more precise than approved products. The Endocrine Society’s position is that little or no scientific evidence shows these custom mixes are safer or more effective than FDA-approved hormone therapies, and that dose and purity can vary. A 2020 National Academies review reached a similar public-health concern: high-quality trials are lacking and oversight is limited. The Menopause Society has long warned that salivary hormone tests do not provide a useful dosing recipe in midlife because levels swing through the day. Approved estradiol and micronized progesterone are chemically identical to ovarian hormones when that is the molecule; the compounding debate is about the untested mix and the marketing, not the word bioidentical. Rare compounding for a documented allergy or shortage is a clinician-pharmacy decision, not a wellness upgrade.
    Sources 3
  • Keep exercise for muscle and bone, not as a proven hot-flash cure. Public advice often says that lifting or yoga will shut off heat. The 2023 nonhormone statement reviewed that literature and did not recommend exercise, yoga, cooling tricks, or trigger-avoidance lists as vasomotor treatment. That is a statement about hot flashes as the outcome, not a claim that movement is useless. WHO activity guidance and LIFTMOR still support strength and impact work for muscle, function, and bone in the right setting. Kohrt’s menopause-exercise research likewise concerns body composition and musculoskeletal aging. A walk or a lift session can still be a good week for other reasons. It should not be sold as a substitute for vasomotor care that the field actually recommends.
    Sources 4

Just talk

  • Check how long heat actually lasts for you. A common saying is that hot flashes last a year or two and then vanish. Avis’s SWAN analysis found a median of more than seven years of frequent symptoms, and longer still for people who were premenopausal or early perimenopausal when frequent heat began. NIA public guidance also describes a wide two-to-eight-year symptom window, with large individual and group differences. Use your own calendar rather than a short folklore timer. If heat is still bothersome, that is a reason to talk with a clinician, not a reason to decide you are imagining it.
    Sources 2
  • Use symptoms and history, not a saliva dosing recipe. Some clinics sell a spit panel that supposedly reveals the exact cream or capsule you need. The Menopause Society and Endocrine Society caution that midlife hormone levels vary by day and hour, and that custom mixes built from those numbers have not been shown to be safer or better than tested products. Jen Gunter's public teaching makes the same practical point: a fluctuating lab is a poor thermostat. Bring symptoms, history, and goals to a clinician. Do not treat a mail-order hormone map as a prescription.
    Sources 3
  • Ask for named nonhormone options instead of herbal blends. Black cohosh, soy extracts, and mixed menopause-support bottles are widely sold as gentle hormone alternatives. The 2023 nonhormone statement does not recommend supplements or herbal remedies as vasomotor treatment, based on mixed or insufficient evidence. A bottle can still cause side effects or mix badly with other medicines. If you want a nonhormone option, the field has named therapies with trial support. Ask a clinician or pharmacist before adding a blend, and do not delay evaluation of heavy bleeding, early period stop, or crushing sleep loss while waiting on a supplement.
    Sources 1
    • The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.Research or guidanceDOI (opens in a new tab) ↗Journal (opens in a new tab) ↗
  • Choose hormone therapy from your history, not from a slogan. One internet camp treats hormone therapy as mandatory anti-aging. Another treats the 2002 WHI headline as a lifetime ban. Neither is the current named-source position. WHI did not support hormones for chronic-disease prevention in the enrolled population. The Menopause Society and Manson's later reviews still treat hormones as the most effective option for bothersome vasomotor symptoms in many healthy people who start nearer menopause and have no contraindication. Pauline Maki's cognition work is one reason late-life initiation is not treated as the same decision as early-symptom care. The useful move is a personal benefit-risk talk, not a slogan.
    Sources 4

What to try

  • Bring one persistent-symptom picture to a clinician. Write four short lines you can actually use in a visit: how cycles have changed, how often heat or night sweats interrupt a day or a night, how sleep is going, and what you want help with first. NIA and NICE both start with that story in midlife rather than with a single lab. Faubion’s public Menopause Society teaching is built around matching treatment to bothersome symptoms and history, not around a universal hormone rule. This is an ordinary preparation step, not a diagnosis and not a request that you start or stop a medicine from a page.
    Sources 3
  • Track cycle changes and heat for a few weeks. Note dates of bleeding, a rough count of daytime flashes and night sweats, and whether sleep broke. STRAW+10 uses persistent cycle-length change and gaps of sixty days as staging clues; Avis counted frequent vasomotor symptoms across years. A brief diary is a translation of those research tools into a visit aid. It does not diagnose you. If bleeding is suddenly very heavy, stacked close together, or returns after a full year without a period, skip the experiment and seek care.
    Sources 3
  • Ask about CBT-I if sleep stays hard. If you have enough time in bed and still cannot sleep, or you wake and cannot return, ask a clinician or sleep program about cognitive behavioral therapy for insomnia. McCurry’s trial used six telephone sessions and improved insomnia scores in women who also had hot flashes. Joffe’s work is a reminder to mention night sweats and mood in the same conversation so the helper can see the whole night. This is a request for structured care, not a demand that you force sleep with more bedtime rules.
    Sources 2
  • Ask about supervised strength and whether bone screening is due. If you already lift, keep the work and ask whether supervision, load, or screening needs a look. If you do not, ask a clinician what kind of strength work is reasonable and whether a DXA conversation fits your age and risk. USPSTF sets population screening ages; LIFTMOR tested a specific supervised high-intensity program in screened women with low bone mass. Neither source is a garage max-out plan. Stop and get assessed for sudden severe pain, a fall with injury, or warning symptoms during exercise.
    Sources 3

How to keep it

  • Keep peri and menopause as different stages. Perimenopause is the transition of changing cycles; menopause is the point after twelve months without a period. Harlow’s STRAW+10 map and NIA public language both protect that distinction. Mixing the words makes people wait for a test that NICE says they often do not need after 45, or assume they are “done” while heat is still running. Use the words that match the calendar you actually have. Staging supports a conversation. It is not a personality.
    Sources 3
  • Keep hormone therapy as a shared decision. The Menopause Society describes a generally favorable balance for many healthy symptomatic women who start under 60 and within ten years of onset, and a less favorable balance later. Manson’s WHI reviews still reject using the same medicines to prevent heart disease. Christmas’s society education stresses matching regimen to the person. Your history, preferences, and contraindications belong in that talk. A friend, a podcast, or this page cannot complete it.
    Sources 3
  • Keep nonhormone options on the table. Shufelt’s 2023 statement exists because many people cannot take estrogen or do not want to. CBT, selected nonhormone medicines, and other named options are field-supported paths for vasomotor bother. Hunter’s CBT work shows that reducing interference can matter even when physiologic flash counts barely move. Choosing a nonhormone path is not a failure to be “on HRT.” It is one of the documented ways the field already treats heat.
    Sources 2
  • Keep strength work as health work. Kohrt and Beck study loading, estrogen, and bone as midlife physiology, not as a contest. WHO’s two-or-more days of muscle-strengthening activity is a population floor. LIFTMOR’s benefit appeared under supervision in a screened group. Do not copy a twenty-year-old’s program, and do not treat sore as a score. Muscle and bone are reasons to keep a repeatable session. They are not proof that heat will stop.
    Sources 3
  • Keep a clinician in the loop for persistent symptoms. NIA tells people who are concerned by menopausal symptoms to talk with a doctor about lifestyle changes or medicines that might help. This packet is the named-source briefing for that visit, not a replacement for it. Recheck if symptoms worsen, if bleeding pattern changes, or if a medicine is not doing the job you hoped. A later appointment is part of ordinary care. It is not evidence that you failed the first plan.
    Sources 1

Sayings people repeat

  • Name menopause after twelve months without a period. Claim: “Menopause means periods have stopped for twelve months” — established. NIA, STRAW+10, and NICE all treat twelve months without a period, outside hormonal contraception, as the usual clinical definition of menopause. Perimenopause is the transition of changing cycles before that point. A page cannot date your last period, and people under 45 or with surgery or contraception need individualized assessment.
    Sources 3
  • Plan for heat that can last years. Claim: “Frequent hot flashes usually last only a year or two” — not what the research found. Avis found a median 7.4 years of frequent vasomotor symptoms in SWAN, with longer courses when frequent heat began before the final period. Two years is folklore, not the cohort result. Duration still varies widely, so use your own pattern and a clinician if the heat is bothersome.
    Sources 1
  • Decide hormone therapy with a clinician, not a slogan. Claim: “Every woman in menopause should take hormone therapy” — not what the research found. The Menopause Society calls hormone therapy the most effective vasomotor treatment and a bone-protecting option in appropriate users. Manson’s WHI reviews still reject using it as chronic-disease prevention, and many people have contraindications or do not want it. Shared decision is the field position, not a mandate.
    Sources 2
  • Keep hormones available as one option, not a ban. Claim: “The WHI proved that no one should ever take hormones” — not what the research found. The 2002 WHI combined-hormone trial answered a prevention question in a mostly older cohort and found overall risks exceeded benefits for that use. Later age-stratified analyses and the 2022 society statement still support treating bothersome vasomotor symptoms in many healthy people who start nearer menopause. A headline ban is not the current reading.
    Sources 3
  • Keep exercise for muscle and bone, not as a hot-flash guarantee. Claim: “Exercise is a proven treatment for hot flashes” — not what the research found. The 2023 nonhormone statement does not recommend exercise or yoga as vasomotor treatment. Strength and activity still matter for muscle, function, and bone. Those are different jobs from shutting off heat.
    Sources 1
    • The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.Research or guidanceDOI (opens in a new tab) ↗Journal (opens in a new tab) ↗
  • Prefer tested hormone products over custom compounded mixes. Claim: “Custom compounded bioidentical hormones are safer than approved products” — not what the research found. The Endocrine Society and a 2020 National Academies review found a lack of high-quality evidence that custom compounded mixes are safer or more effective, and warned about variable dose and purity. Saliva tests are not a useful midlife dosing recipe. Approved products can already include body-identical estradiol and progesterone when that molecule is chosen.
    Sources 2
  • Use structured insomnia care when nights stay broken. Claim: “CBT-I can improve insomnia during the menopause transition” — established. McCurry’s MsFLASH randomized trial found larger, lasting insomnia-score improvements with telephone CBT-I than with menopause education in peri- and postmenopausal women who also had hot flashes. Joffe’s work supports treating sleep as its own problem alongside vasomotor symptoms. CBT-I is structured care, not a guarantee, and breathing pauses still need clinical evaluation.
    Sources 2

The longer notes

  • Use STRAW stages as a map, not a self-diagnosis. STRAW+10, led by Harlow, divides reproductive aging around the final menstrual period. Early transition means a persistent seven-day or greater difference in consecutive cycle lengths. Late transition means a gap of sixty days or more, often lasting one to three years. The twelve months after the last period close ordinary perimenopause; later postmenopause continues after hormones stabilize. The system was built so studies of midlife women could be compared, and it applies across age, ethnicity, body size, and lifestyle in the workshop’s judgment. Hormonal contraception, hysterectomy, and periods that stop before 40 need a different clinical approach. Use the map to describe what is happening. Do not treat it as a lab you can run on yourself.
    Sources 2
  • Read the WHI with its original prevention question and the later age split. Rossouw’s 2002 estrogen-plus-progestin report stopped the combined trial early because overall risks exceeded benefits for chronic-disease prevention in a cohort whose mean age was about 63. Coronary events, stroke, pulmonary embolism, and invasive breast cancer were higher on the global index, while hip fracture and colorectal cancer were lower; all-cause mortality was not increased during the trial. Manson’s 2013 thirteen-year overview and 2024 practice review keep that prevention answer and add the age split: absolute harms were smaller in the 50-to-59 group, and hormones remain a vasomotor treatment option in early menopause without contraindications. Carolyn Crandall, a WHI investigator and NAMS panelist, helps keep bone and breast findings attached to the regimen actually studied. The reanalysis refined who faces which absolute risk. It did not convert the trial into a universal hormone mandate.
    Sources 4
  • Distinguish estrogen-alone from combined therapy breast findings. In WHI, women with a uterus received oral conjugated estrogen plus medroxyprogesterone acetate; women with a hysterectomy received estrogen alone. During combined-therapy intervention, invasive breast cancer was higher than placebo. In the estrogen-alone trial, breast-cancer incidence was not increased and, with longer follow-up, was lower than placebo in Manson’s 2013 cumulative analysis. Those are different regimens, not proof that “estrogen is safe” or “hormones cause cancer” as a single sentence. A person with a uterus who uses systemic estrogen still needs endometrial protection with a progestogen, which is a separate, well-established gynecologic rule in the 2022 position statement. Breast-risk talk belongs with the actual product, duration, and personal history. It is not settled by a headline from one arm.
    Sources 3
  • Ask about skin versus pill when clotting risk is part of the talk. The 2022 Menopause Society statement notes that transdermal routes and lower doses may decrease risk of venous thromboembolism and stroke compared with higher-dose oral regimens. That is a comparative safety signal from observational and mechanistic work, not a randomized promise that a patch erases clot risk. Oral combined therapy in WHI increased pulmonary embolism. Shufelt’s women’s-heart research is one reason cardiology and menopause care now ask about route, dose, and baseline clot or stroke history. If a clinician is considering hormones and you have migraine with aura, prior clots, or other vascular history, that history belongs in the first sentence, not as an afterthought. Route is a shared-decision detail. It is not a DIY swap.
    Sources 3
  • Use CBT to reduce how much heat bothers daily life. Myra Hunter developed brief cognitive-behavioral therapy for hot flushes and night sweats and tested group and self-help versions in women with natural menopause and in women after breast-cancer treatment. Those trials, now reflected in NICE and in the 2023 nonhormone statement, found substantial reductions in how much heat interfered with life, with smaller or mixed effects on physiologic flash counts depending on the group. The method works on attention, appraisal, and behavioral responses to an episode, not by adding estrogen. Carpenter’s symptom-science work likewise separates frequency from bother. If the goal is to get through a meeting or a night with less distress, CBT is a named tool. It is not a claim that the nervous system has invented the flash.
    Sources 2
  • Separate night sweats from an independent insomnia pattern. Joffe’s reviews describe two overlapping problems: awakenings tied to vasomotor events, and sleep disturbance that remains after those events and mood are considered. McCurry’s CBT-I group slept better and reported less hot-flash interference without a change in daily flash frequency versus education. That pattern is why treating insomnia can help a menopause-related night even when heat continues. It is also why a wearable score is not a diagnosis. If the main complaint is heat, vasomotor treatment may be the first lever. If the main complaint is not being able to sleep despite time in bed, ask for insomnia care. Many people need both conversations. Neither is a moral failure.
    Sources 2
  • Use supervised heavy lifting as a researched bone option. LIFTMOR randomized postmenopausal women with osteopenia or osteoporosis, after screening out selected medical problems, to eight months of twice-weekly, thirty-minute, supervised high-intensity resistance and impact training or a home low-intensity program. The lifting group used five sets of five repetitions above 85 percent of one-repetition maximum. Lumbar-spine density and functional tests improved more than in the control group; one minor back spasm was the reported adverse event under that supervision. Beck’s group designed the protocol because ordinary walking often does not load bone enough to change density. This is evidence that heavy, coached loading can be studied safely in screened women. It is not permission to load a bar to failure alone in a garage, and it is not a fracture-treatment plan after a break.
    Sources 2
  • Bring periods that stop early to a clinician. Premature ovarian insufficiency means ovaries stop working before 40; early menopause usually means the final period between 40 and 45. The 2022 Menopause Society statement says these groups have higher risks of bone loss, heart disease, and cognitive or affective disorders associated with estrogen deficiency, and that hormone therapy can be used until at least the mean age of menopause unless there is a contraindication. Santoro has long argued that this is a different clinical problem from typical-age menopause. NIA notes that surgery that removes both ovaries can create an immediate menopause. This packet cannot sort those causes. It can say that an early stop is a reason for evaluation rather than a reason to adopt a “never take hormones” slogan meant for a different group.
    Sources 3

Who this is drawing from

Related

Good to know

  • Good to know. This is a reading companion, not a diagnosis, hormone prescription, or clinic visit. Persistent or bothersome heat, night sweats, broken sleep, early period stop, or worry about bone belong with a qualified clinician who can take a history and tailor care. After more than a year without a period, new bleeding or spotting needs prompt medical review. Periods that stop before 45, very heavy or closely stacked bleeding, and sudden severe symptoms also need a person, not a page. Do not start, stop, or change hormone therapy, other medicines, or a training plan from this text. Chest pain, fainting, one-sided weakness, or sudden breathlessness need emergency care. This page does not treat one body or promise an outcome.
    Sources 3
  • Not advice. Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.

Also on this house

STUDself. For how people talk about sleep hours, see STUDself. For lifting after 40, see STUDfit.

All STUDlearn topics →